Legal & General Group
BCAX

Legal & General Group’s Bicara Therapeutics BCAX Stock Holding History

Legal & General Group’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$704K Buy
23,703
+1,476
+7% +$32.9K ﹤0.01% 2305
2026
Q1 		$442K Buy
22,227
+6,269
+39% +$108K ﹤0.01% 2391
2025
Q4 		$269K Buy
15,958
+12,802
+406% +$219K ﹤0.01% 2548
2025
Q3 		$49.8K Hold
3,156
– – ﹤0.01% 2731
2025
Q2 		$29.3K Buy
3,156
+1,233
+64% +$14.7K ﹤0.01% 2862
2025
Q1 		$25.1K Hold
1,923
– – ﹤0.01% 2869
2024
Q4 		$33.4K Buy
+1,923
New +$40K ﹤0.01% 2859

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Legal & General Group's BCAX Position: Q2 2026 in Review

Legal & General Group increased its Bicara Therapeutics (BCAX) stake by 6.6% in Q2 2026, buying an estimated $32.9K and bringing the position to 23,703 shares worth $704K. The position accounts for ﹤0.01% of the portfolio, ranked #2305.

Legal & General Group first reported a position in BCAX in Q4 2024 and has held it in 7 quarters since. 172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Legal & General Group held 23,703 shares of Bicara Therapeutics worth $704K as of Q2 2026.
  • Legal & General Group bought 1,476 Bicara Therapeutics shares in Q2 2026, an estimated $32.9K.
  • Bicara Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #2305 holding.
  • Legal & General Group first reported a position in Bicara Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.